Answers are grounded in this paper and cite their sources.
Prospective observational study reports maculopapular rash features in patients on immune checkpoint inhibitors, indicating management gaps.
Incidence and features of maculopapular rashes in patients receiving immune checkpoint inhibitors ଝ Dear Editor, Maculopapular Rash (MPR) is reported as one of the most frequent cutaneous immune-related Adverse Events (cirAEs) in patients receiving Immune Checkpoint Inhibitors (ICIs).1---3 However, the incidence, features, and management of MPR in real-world clinical practice remain unclear.We performed a real-world, prospective, observational study in the Department of Dermatology of Alicante University General Hospital (a Spanish tertiary care hospital) including all adults who were starting ICI therapy between 1 March 2020 and 31 May 2022.Clinical trial participants were excluded.Fig. 1 (A---B) Patient 2. 65-year-old patient with stage IV lung adenocarcinoma presenting with a Grade 3 Maculopapular Rash (MPR): confluent and slightly scaly maculopapular lesions with intense erythema in the trunk and extremities covering > 30% Body Surface Area (BSA).
No takes yet. Share an insight, caveat, or question.
Juan‐Carpena et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: